
Annual report 2024
added 12-27-2025
Brainsway Ltd. Net Income 2011-2025 | BWAY
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Brainsway Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -6.46 M | -5.38 M | -10.3 M | -6.48 M | -7.05 M | -2.4 M | -4.09 M | -6.54 M | -7.12 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.4 M | -10.3 M | -6.21 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.97 | -1.38 % | $ 226 M | ||
|
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | ||
|
Co-Diagnostics
CODX
|
-35.3 M | $ 0.23 | -4.4 % | $ 6.75 M | ||
|
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | ||
|
Castle Biosciences
CSTL
|
18.2 M | $ 39.53 | -1.4 % | $ 1.1 B | ||
|
BioNano Genomics
BNGO
|
-112 M | $ 1.52 | - | $ 1.93 M | ||
|
DarioHealth Corp.
DRIO
|
-59.4 M | $ 10.17 | 1.29 % | $ 289 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M | ||
|
DexCom
DXCM
|
542 M | $ 67.51 | 0.13 % | $ 26.1 B | ||
|
Danaher Corporation
DHR
|
3.9 B | $ 230.0 | -0.45 % | $ 168 B | ||
|
Exact Sciences Corporation
EXAS
|
-865 M | $ 101.56 | 0.02 % | $ 18.8 B | ||
|
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
-42.7 M | $ 26.78 | -0.85 % | $ 810 M | ||
|
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-190 M | $ 19.47 | -1.32 % | $ 1.05 B | ||
|
Celcuity
CELC
|
-112 M | $ 101.9 | -0.7 % | $ 4.02 B | ||
|
Anixa Biosciences
ANIX
|
-12.6 M | $ 3.21 | -6.25 % | $ 102 K | ||
|
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
1.37 B | $ 226.52 | 0.26 % | $ 41.1 B | ||
|
Guardant Health
GH
|
-436 M | $ 103.35 | 0.94 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | ||
|
Myriad Genetics
MYGN
|
-127 M | $ 6.44 | -1.68 % | $ 583 M | ||
|
Illumina
ILMN
|
-1.22 B | $ 135.12 | -0.15 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
22.2 M | $ 203.88 | - | $ 10.5 B | ||
|
ENDRA Life Sciences
NDRA
|
-11.5 M | $ 4.94 | -3.14 % | $ 2.65 M | ||
|
Neogen Corporation
NEOG
|
-1.09 B | $ 7.12 | -0.35 % | $ 1.54 B | ||
|
National Research Corporation
NRC
|
31 M | $ 18.74 | 0.46 % | $ 460 M | ||
|
Quest Diagnostics Incorporated
DGX
|
871 M | $ 176.16 | 0.15 % | $ 19.6 B | ||
|
Biodesix
BDSX
|
-42.9 M | $ 6.76 | -0.88 % | $ 877 M | ||
|
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
746 M | $ 254.32 | 0.02 % | $ 21.3 B | ||
|
ICON Public Limited Company
ICLR
|
791 M | $ 182.75 | -0.51 % | $ 15.1 B | ||
|
IDEXX Laboratories
IDXX
|
888 M | $ 688.22 | 0.01 % | $ 56.8 B | ||
|
Pacific Biosciences of California
PACB
|
-307 M | $ 1.77 | -5.85 % | $ 449 M | ||
|
Lantheus Holdings
LNTH
|
312 M | $ 66.73 | 0.07 % | $ 4.62 B | ||
|
Mettler-Toledo International
MTD
|
863 M | $ 1 419.64 | 0.11 % | $ 30.1 B | ||
|
Agilent Technologies
A
|
1.21 B | $ 138.31 | 0.03 % | $ 42 B | ||
|
Biomerica
BMRA
|
-4.97 M | $ 2.7 | 1.9 % | $ 6.2 M | ||
|
Bioventus
BVS
|
-156 M | $ 7.4 | 0.27 % | $ 464 M | ||
|
NeoGenomics
NEO
|
-78.7 M | $ 12.33 | 0.2 % | $ 1.56 B |